Pieris Pharmaceuticals PIRS Stock
Pieris Pharmaceuticals Price Chart
Pieris Pharmaceuticals PIRS Financial and Trading Overview
| Pieris Pharmaceuticals stock price | 0.14 USD |
| Previous Close | 0.91 USD |
| Open | 0.89 USD |
| Bid | 0 USD x 1300 |
| Ask | 0 USD x 900 |
| Day's Range | 0.87 - 0.93 USD |
| 52 Week Range | 0.72 - 2.12 USD |
| Volume | 149.47K USD |
| Avg. Volume | 741.29K USD |
| Market Cap | 73.01M USD |
| Beta (5Y Monthly) | 1.078873 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.27 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
PIRS Valuation Measures
| Enterprise Value | 38.94M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.2362499 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 4.3326535 |
| Price/Book (mrq) | 4.3 |
| Enterprise Value/Revenue | 2.311 |
| Enterprise Value/EBITDA | -0.795 |
Trading Information
Pieris Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 1.078873 |
| 52-Week Change | -46.70% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 2.12 USD |
| 52 Week Low | 0.72 USD |
| 50-Day Moving Average | 0.83 USD |
| 200-Day Moving Average | 1.14 USD |
PIRS Share Statistics
| Avg. Volume (3 month) | 741.29K USD |
| Avg. Daily Volume (10-Days) | 220.51K USD |
| Shares Outstanding | 82.02M |
| Float | 38.57M |
| Short Ratio | 1.29 |
| % Held by Insiders | 9.84% |
| % Held by Institutions | 59.36% |
| Shares Short | 1.85M |
| Short % of Float | 2.29% |
| Short % of Shares Outstanding | 2.25% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -245.45% |
| Operating Margin (ttm) | -305.80% |
| Gross Margin | -210.62% |
| EBITDA Margin | -290.78% |
Management Effectiveness
| Return on Assets (ttm) | -29.36% |
| Return on Equity (ttm) | -120.040% |
Income Statement
| Revenue (ttm) | 16.85M USD |
| Revenue Per Share (ttm) | 0.23 USD |
| Quarterly Revenue Growth (yoy) | -82.39% |
| Gross Profit (ttm) | -27080000 USD |
| EBITDA | -48998000 USD |
| Net Income Avi to Common (ttm) | -41359000 USD |
| Diluted EPS (ttm) | -0.54 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 48.38M USD |
| Total Cash Per Share (mrq) | 0.59 USD |
| Total Debt (mrq) | 13.09M USD |
| Total Debt/Equity (mrq) | 84.67 USD |
| Current Ratio (mrq) | 1.411 |
| Book Value Per Share (mrq) | 0.207 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -48285000 USD |
| Levered Free Cash Flow (ttm) | -23408000 USD |
Profile of Pieris Pharmaceuticals
| Country | United States |
| State | MA |
| City | Boston |
| Address | 225 Franklin Street |
| ZIP | 02110 |
| Phone | 857 246 8998 |
| Website | https://www.pieris.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 127 |
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin based drug candidate, elarekibep used for the treatment of asthma; and PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis. The company also develops PRS-344/S09501 2that consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
Q&A For Pieris Pharmaceuticals Stock
What is a current PIRS stock price?
Pieris Pharmaceuticals PIRS stock price today per share is 0.14 USD.
How to purchase Pieris Pharmaceuticals stock?
You can buy PIRS shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Pieris Pharmaceuticals?
The stock symbol or ticker of Pieris Pharmaceuticals is PIRS.
Which industry does the Pieris Pharmaceuticals company belong to?
The Pieris Pharmaceuticals industry is Biotechnology.
How many shares does Pieris Pharmaceuticals have in circulation?
The max supply of Pieris Pharmaceuticals shares is 117.97M.
What is Pieris Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Pieris Pharmaceuticals PE Ratio is now.
What was Pieris Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Pieris Pharmaceuticals EPS is -0.27 USD over the trailing 12 months.
Which sector does the Pieris Pharmaceuticals company belong to?
The Pieris Pharmaceuticals sector is Healthcare.
Pieris Pharmaceuticals PIRS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Capital Market Composite RCMP | 114.55 USD — |
-2.27
|
— — | 114.09 USD — | 116.72 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| NASDAQ Composite Total Return I XCMP | 19659.36 USD — |
-1.62
|
— — | 19598.88 USD — | 19861.56 USD — | — - | — — |
- {{ link.label }} {{link}}